228 related articles for article (PubMed ID: 38363137)
1. Nanobody engineering for SARS-CoV-2 neutralization and detection.
Hannula L; Kuivanen S; Lasham J; Kant R; Kareinen L; Bogacheva M; Strandin T; Sironen T; Hepojoki J; Sharma V; Saviranta P; Kipar A; Vapalahti O; Huiskonen JT; Rissanen I
Microbiol Spectr; 2024 Apr; 12(4):e0419922. PubMed ID: 38363137
[TBL] [Abstract][Full Text] [Related]
2. A Multivalent and Thermostable Nanobody Neutralizing SARS-CoV-2 Omicron (B.1.1.529).
Lu Y; Li Q; Fan H; Liao C; Zhang J; Hu H; Yi H; Peng Y; Lu J; Chen Z
Int J Nanomedicine; 2023; 18():353-367. PubMed ID: 36700149
[TBL] [Abstract][Full Text] [Related]
3. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering.
Verkhivker G
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351
[TBL] [Abstract][Full Text] [Related]
4. Deep mutational engineering of broadly-neutralizing nanobodies accommodating SARS-CoV-1 and 2 antigenic drift.
Laroche A; Orsini Delgado ML; Chalopin B; Cuniasse P; Dubois S; Sierocki R; Gallais F; Debroas S; Bellanger L; Simon S; Maillère B; Nozach H
MAbs; 2022; 14(1):2076775. PubMed ID: 35593235
[TBL] [Abstract][Full Text] [Related]
5. Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters.
Aksu M; Kumar P; Güttler T; Taxer W; Gregor K; Mußil B; Rymarenko O; Stegmann KM; Dickmanns A; Gerber S; Reineking W; Schulz C; Henneck T; Mohamed A; Pohlmann G; Ramazanoglu M; Mese K; Groß U; Ben-Yedidia T; Ovadia O; Fischer DW; Kamensky M; Reichman A; Baumgärtner W; von Köckritz-Blickwede M; Dobbelstein M; Görlich D
Antiviral Res; 2024 Jan; 221():105778. PubMed ID: 38065245
[TBL] [Abstract][Full Text] [Related]
6. An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants.
Chi X; Zhang X; Pan S; Yu Y; Shi Y; Lin T; Duan H; Liu X; Chen W; Yang X; Chen L; Dong X; Ren L; Ding Q; Wang J; Yang W
Signal Transduct Target Ther; 2022 Feb; 7(1):44. PubMed ID: 35140196
[TBL] [Abstract][Full Text] [Related]
7. Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants.
Xu J; Xu K; Jung S; Conte A; Lieberman J; Muecksch F; Lorenzi JCC; Park S; Schmidt F; Wang Z; Huang Y; Luo Y; Nair MS; Wang P; Schulz JE; Tessarollo L; Bylund T; Chuang GY; Olia AS; Stephens T; Teng IT; Tsybovsky Y; Zhou T; Munster V; Ho DD; Hatziioannou T; Bieniasz PD; Nussenzweig MC; Kwong PD; Casellas R
Nature; 2021 Jul; 595(7866):278-282. PubMed ID: 34098567
[TBL] [Abstract][Full Text] [Related]
8. Structural basis of nanobodies neutralizing SARS-CoV-2 variants.
Shi Z; Li X; Wang L; Sun Z; Zhang H; Chen X; Cui Q; Qiao H; Lan Z; Zhang X; Li X; Li L; Xu J; Gong R; Fan C; Geng Y
Structure; 2022 May; 30(5):707-720.e5. PubMed ID: 35276082
[TBL] [Abstract][Full Text] [Related]
9. Structure-guided design of a trivalent nanobody cluster targeting SARS-CoV-2 spike protein.
Jiang X; Qin Q; Zhu H; Qian J; Huang Q
Int J Biol Macromol; 2024 Jan; 256(Pt 1):128191. PubMed ID: 38000614
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19.
Ye G; Pan R; Bu F; Zheng J; Mendoza A; Wen W; Du L; Spiller B; Wadzinski BE; Liu B; Perlman S; Li F
J Virol; 2023 Nov; 97(11):e0144823. PubMed ID: 37855638
[TBL] [Abstract][Full Text] [Related]
11. A Naïve Phage Display Library-Derived Nanobody Neutralizes SARS-CoV-2 and Three Variants of Concern.
Wu D; Cong J; Wei J; Hu J; Sun W; Ran W; Liao C; Zheng H; Ye L
Int J Nanomedicine; 2023; 18():5781-5795. PubMed ID: 37869063
[TBL] [Abstract][Full Text] [Related]
12. Development of a bispecific nanobody conjugate broadly neutralizes diverse SARS-CoV-2 variants and structural basis for its broad neutralization.
Yang J; Lin S; Chen Z; Yang F; Guo L; Wang L; Duan Y; Zhang X; Dai Y; Yin K; Yu C; Yuan X; Sun H; He B; Cao Y; Ye H; Dong H; Liu X; Chen B; Li J; Zhao Q; Lu G
PLoS Pathog; 2023 Nov; 19(11):e1011804. PubMed ID: 38033141
[TBL] [Abstract][Full Text] [Related]
13. A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike.
Fu Y; da Fonseca Rezende E Mello J; Fleming BD; Renn A; Chen CZ; Hu X; Xu M; Gorshkov K; Hanson Q; Zheng W; Lee EM; Perera L; Petrovich R; Pradhan M; Eastman RT; Itkin Z; Stanley TB; Hsu A; Dandey V; Sharma K; Gillette W; Taylor T; Ramakrishnan N; Perkins S; Esposito D; Oh E; Susumu K; Wolak M; Ferrer M; Hall MD; Borgnia MJ; Simeonov A
PLoS One; 2022; 17(8):e0272364. PubMed ID: 35947606
[TBL] [Abstract][Full Text] [Related]
14. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
15. Structure-guided multivalent nanobodies block SARS-CoV-2 infection and suppress mutational escape.
Koenig PA; Das H; Liu H; Kümmerer BM; Gohr FN; Jenster LM; Schiffelers LDJ; Tesfamariam YM; Uchima M; Wuerth JD; Gatterdam K; Ruetalo N; Christensen MH; Fandrey CI; Normann S; Tödtmann JMP; Pritzl S; Hanke L; Boos J; Yuan M; Zhu X; Schmid-Burgk JL; Kato H; Schindler M; Wilson IA; Geyer M; Ludwig KU; Hällberg BM; Wu NC; Schmidt FI
Science; 2021 Feb; 371(6530):. PubMed ID: 33436526
[TBL] [Abstract][Full Text] [Related]
16. Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance.
Walter JD; Scherer M; Hutter CAJ; Garaeva AA; Zimmermann I; Wyss M; Rheinberger J; Ruedin Y; Earp JC; Egloff P; Sorgenfrei M; Hürlimann LM; Gonda I; Meier G; Remm S; Thavarasah S; van Geest G; Bruggmann R; Zimmer G; Slotboom DJ; Paulino C; Plattet P; Seeger MA
EMBO Rep; 2022 Apr; 23(4):e54199. PubMed ID: 35253970
[TBL] [Abstract][Full Text] [Related]
17. A cell-free nanobody engineering platform rapidly generates SARS-CoV-2 neutralizing nanobodies.
Chen X; Gentili M; Hacohen N; Regev A
Nat Commun; 2021 Sep; 12(1):5506. PubMed ID: 34535642
[TBL] [Abstract][Full Text] [Related]
18. Development of multivalent nanobodies blocking SARS-CoV-2 infection by targeting RBD of spike protein.
Lu Q; Zhang Z; Li H; Zhong K; Zhao Q; Wang Z; Wu Z; Yang D; Sun S; Yang N; Zheng M; Chen Q; Long C; Guo W; Yang H; Nie C; Tong A
J Nanobiotechnology; 2021 Jan; 19(1):33. PubMed ID: 33514385
[TBL] [Abstract][Full Text] [Related]
19. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant.
Verkhivker G
Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287
[TBL] [Abstract][Full Text] [Related]
20. Rapid and Quantitative
Wu W; Tan X; Zupancic J; Schardt JS; Desai AA; Smith MD; Zhang J; Xie L; Oo MK; Tessier PM; Fan X
Anal Chem; 2022 Mar; 94(10):4504-4512. PubMed ID: 35238533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
